Anticancer

Ziyuglycoside II
Catalog No: CFN98465

Ziyuglycoside II has a wide range of clinical applications including hemostasis, antibiosis, anti-inflammation and anti-oxidation. Ziyuglycoside II has inhibitory effect on the growth of MDA-MB-435 cells, it induces cell cycle arrest and apoptosis through activation of ROS/JNK pathway in human breast cancer cells.Ziyuglycoside II methyl ester possess improved anti-diabetic properties, and has hepato-renal protective activities in type 2 diabetes.
Norathyriol
Catalog No: CFN98468

Norathyriol is a potent PTP1B inhibitor with good cell permeability and oral availability. Norathyriol as a safe new chemopreventive agent that is highly effective against development of UV-induced skin cancer. Norathyriol may be a dual, yet weak, cyclooxygenase and lipoxygenase pathway blocker, it has anti-inflammatory effect, and has inhibitory effect on the A23187-induced pleurisy and acetic acid-induced writhing response in mice. Norathyriol can relax the rat thoracic aorta mainly by suppressing the Ca2+ influx through both voltage-dependent and receptor-operated calcium channels. Norathyriol also can improve the glucose utilization and insulin sensitivity by up-regulation of the phosphorylation of AMPK.
Baohuoside I
Catalog No: CFN98525

Baohuoside I is a novel immunosuppressive molecule, exhibits antimetastatic, anti-osteoporosis, anti-inflammatory and anti-cancer activities. Baohuoside I can inhibit the proliferation of Eca-109 cells, this effect associats with down-regulation expression of β-catenin,Cyclin D1,Survivin,and their proteins,which affects on the Wnt/β-catenin signaling pathway.
Icaritin
Catalog No: CFN98527

Icaritin, a potent inhibitor of transcription factor SREBPs, which exhibits a variety of biological activities, such as activation of cancer cell apoptosis and inhibition of growth, hormone regulation, protection against beta amyloid-induced neurotoxicity, and promotion of neuronal and cardiac cellular differentiation. Icaritin shows potent anti-leukemia activity on chronic myeloid leukemia in vitro and in vivo by regulating MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings.
Cryptotanshinone
Catalog No: CFN98478

Cryptotanshinone is a potent STAT3 inhibitor with IC50 of 4.6 μM, and inhibits STAT3 Tyr705 phosphorylation in DU145 prostate cancer cells. It is also an AR inhibitor to suppress androgen/AR-mediated cell growth and PSA expression by blocking AR dimerization and the AR-coregulator complex formation. Cryptotanshinone has anti-atherosclerosis, neuroprotective, anti-cancer,and anti-neointimal formation activities. Cryptotanshinone reverses DEX-induced androgen excess and ovarian IR in mice through activation of insulin signaling and the regulation of glucose transporters and hormone-synthesizing enzymes, it has an inhibitory effect on MMP-9 production and migration of human aortic smooth muscle cells treated with TNF-alpha in a dose-dependent manner.